Ignite Creation Date:
2024-05-05 @ 11:36 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00096980
Status:
COMPLETED
Last Update Posted:
2013-06-21
First Post:
2004-11-17
Brief Title:
A Study to Evaluate Raptiva in Combination With Topical Psoriasis Therapies
Sponsor:
Genentech Inc
Organization:
Genentech Inc
Study Overview
Official Title:
An Open Label Randomized Multicenter Study to Evaluate the Safety Tolerability and Efficacy of Subcutaneously Administered Efalizumab Used in Combination With Topical Psoriasis Therapies for Prolonged Maintenance Treatment
Status:
COMPLETED
Status Verified Date:
2013-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is an open label randomized multicenter study designed to compare the efficacy of 12 weeks of subcutaneously administered efalizumab monotherapy with that of combination therapy Efalizumab and a topical corticosteroid ointment in subjects with moderate to severe plaque psoriasis who are candidates for systemic therapy The study will also evaluate the safety and tolerability of 30 months of continuous efalizumab treatment in those subjects who derive benefit from the initial 12 weeks of treatment
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None